Network origin in Carlos Guillem first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Renibus Therapeutics, Inc.
 Renibus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Renibus Therapeutics, Inc. engages in manufacture of pharmaceutical products. The company was founded by Donald Jeffrey Keyser and Alvaro F. Guillem in 2015 and is headquartered in Southlake, TX.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Carlos Guillem via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ZS PHARMA INC | Pharmaceuticals: Major | Founder Chief Tech/Sci/R&D Officer | |
| Adams Laboratories, Inc. | General Counsel | ||
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Neoprogen, Inc.
 Neoprogen, Inc. BiotechnologyHealth Technology Neoprogen, Inc. engages in the development of cell-based therapy for people who experience a heart attack. The company was founded by Sunjay Kaushal, Rachana Mishra and Sudhish Sharma and is headquartered in Baltimore, MD. | Biotechnology | Director/Board Member | |
| ALLAKOS INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Alba Therapeutics Corp.
 Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| GENVEC INC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Nabi Pharmaceuticals | Chief Tech/Sci/R&D Officer | ||
| Novo-Nordisk Biochem, Inc. | Chief Tech/Sci/R&D Officer | ||
| Rasmussen Biotech & Pharma Consulting LLC | Chief Executive Officer | ||
| University of Copenhagen | College/University | Doctorate Degree | |
| VERNALIS | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Creighton University | College/University | Graduate Degree | |
| LANTERN PHARMA INC. | Pharmaceuticals: Major | Chairman | |
| The University of Texas at Dallas | College/University | Doctorate Degree | |
| University of Missouri-Kansas City | College/University | Graduate Degree | |
| ABBOTT LABORATORIES | Medical Specialties | Corporate Officer/Principal | |
| Medeva Americas, Inc. | General Counsel | ||
Encysive Pharmaceuticals, Inc.
 Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | Pharmaceuticals: Major | Compliance Officer |
Statistics
International
| United States | 22 |
| France | 2 |
| Denmark | 2 |
| United Kingdom | 2 |
Sectoral
| Health Technology | 14 |
| Consumer Services | 5 |
| Health Services | 2 |
| Distribution Services | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 9 |
| General Counsel | 7 |
| Director/Board Member | 6 |
| Corporate Officer/Principal | 5 |
| Founder | 5 |
Most connected contacts
| Insiders | |
|---|---|
| Henrik Rasmussen | 14 |
| Donald Keyser | 13 |
| Bhupinder Singh | 1 |
- Stock Market
- Insiders
- Carlos Guillem
- Company connections
